Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD

The Indian pharmaceutical industry, faced with dwindling returns in its established traditional generics operations, must transition to a model that encompasses complex generics, biosimilars and specialty medicines to ensure sustained progress, according to Lupin Ltd.’s managing director Nilesh Gupta.

Quoting Bob Dylan, Gupta declared that “the times they are a-changin’” and the Indian industry is nearing the end of its “second wave”, which entailed dominating the generics space in developed markets. It is now in the investment phase for the next wave, with returns likely to kick in only in the next two years